Atara Biotherapeutics Inc
Statements
Cash Flow
Atara Biotherapeutics Inc (ATRA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -3.3 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16 | -21 | -22 | -20 | -20 | -25 | -35 | -39 | -48 | -57 | -70 | -55 | -52 | -59 | -67 | -57 | -53 | -4.1 | -66 | -62 | -59 | -34 | -85 | -64 | -65 | -57 | -38 | -53 | -51 | -50 | -30 | -11 | -4.0 | -24 | -28 | -7.3 | -9.8 | -5.7 | -3.1 | -3.3 | -22 | |
| 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.7 | 1.2 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.9 | 2.1 | 2.2 | 2.2 | 2.2 | 2.3 | 2.3 | 2.5 | 1.6 | 1.4 | 1.4 | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.4 | 1.3 | 1.2 | 1.1 | 1.8 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 5.3 | 1.7 | 5.3 | 5.7 | 6.0 | 6.1 | 7.0 | 8.0 | 9.3 | 9.6 | 12 | 15 | 12 | 12 | 13 | 14 | 13 | 12 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 11 | 12 | 13 | 11 | 9.9 | 8.4 | 6.3 | 6.4 | 5.8 | 4.2 | 2.8 | 1.2 | 1.5 | 0.7 | 0.4 | 3.9 | |
| 5.3 | 1.7 | 5.3 | 5.7 | 6.0 | 6.1 | 7.1 | 8.1 | 9.3 | 9.6 | 12 | 15 | 13 | 12 | 13 | 14 | 13 | 12 | 12 | 15 | 14 | 15 | 14 | -36 | 14 | 11 | 12 | 13 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 3.9 | -4.5 | -2.2 | 1.1 | 4.5 | 3.9 | -0.6 | 3.2 | 0.3 | 12 | -17 | 3.0 | 4.6 | 5.7 | -8.6 | 4.2 | 5.3 | 63 | -2.6 | 5.2 | 8.7 | 41 | -13 | -51 | 0.7 | 2.1 | 20 | 1.1 | 2.0 | -7.3 | -12 | -3.4 | 6.6 | -22 | -82 | -13 | -7.9 | -2.0 | -0.8 | 0.7 | -9.9 | |
| 0.4 | 1.0 | 1.2 | 3.1 | 6.2 | 9.7 | 20 | 7.4 | 4.5 | 4.2 | 0.8 | 0.7 | 1.5 | 2.7 | 1.3 | 2.1 | 0.5 | 0.6 | 2.2 | 2.1 | 3.9 | 2.5 | 2.6 | 1.4 | 0.1 | 0.0 | 0.4 | 0.5 | 0.3 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 35 | 23 | 37 | 12 | 6.6 | 43 | -250 | -3.9 | 11 | 46 | 68 | 50 | -59 | 1.1 | 39 | -130 | 7.6 | -37 | 13 | 32 | 1.2 | -24 | 60 | 32 | 60 | 51 | -6.0 | 49 | 70 | 9.9 | 15 | 7.2 | -17 | 3.4 | 17 | -5.1 | -2.4 | 8.4 | – | -6.6 | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | 0.1 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | -3.4 | -0.1 | -4.1 | 0.0 | -4.6 | -2.1 | 0.0 | 38 | -1.4 | 1.8 | -0.1 | 14 | -1.2 | 0.0 | 47 | 52 | -0.6 | 0.0 | 0.0 | 1.8 | -0.1 | 0.0 | – | 0.1 | 0.0 | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| – | -0.5 | 0.3 | 11 | -4.7 | 3.7 | -0.1 | -0.2 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | 30 | -0.3 | -0.2 | – | – | – | – | -0.2 | -0.2 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.2 | 0.3 | -0.3 | 9.8 | 9.9 | 0.7 | 296 | 56 | -0.5 | 6.0 | -1.9 | 7.3 | 146 | 37 | 24 | 191 | 34 | 179 | 2.9 | 2.4 | 47 | 51 | 20 | 1.2 | -0.2 | 32 | 0.2 | 0.5 | -0.2 | 1.5 | 24 | -0.3 | 36 | -0.3 | -0.3 | 15 | 1.0 | 0.0 | 3.0 | 4.8 | 8.8 | |
| 20 | 2.0 | 14 | 1.8 | -3.7 | 19 | 11 | 13 | -37 | -5.3 | -4.5 | 3.0 | 35 | -20 | -4.1 | 4.3 | -12 | 138 | -49 | -27 | -11 | -7.1 | -4.5 | -31 | -5.6 | 27 | -44 | -2.8 | 19 | -39 | 9.2 | -3.8 | 15 | -21 | -11 | 2.9 | -11 | 2.7 | -0.1 | -5.1 | -14 | |
| -16 | -22 | -23 | -23 | -26 | -35 | -55 | -47 | -53 | -62 | -71 | -55 | -54 | -61 | -68 | -59 | -53 | -4.7 | -68 | -64 | -63 | -37 | -87 | -65 | -65 | -57 | -39 | -53 | -52 | -50 | -30 | -11 | -4.0 | -25 | -28 | -7.3 | -9.8 | -5.7 | -3.1 | -3.3 | -22 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.